Internal Medicine
Partner With Us
Advertisement
Conexiant chevron_right Internal Medicine chevron_right 18-Year Neuroblastoma Remission in a Patient After GD2 CAR T-Cell Therapy
From the Journals

18-Year Neuroblastoma Remission in a Patient After GD2 CAR T-Cell Therapy

"She has never required any other therapy and is likely the longest-surviving patient with cancer who received [CAR T-cell] therapy."

Conexiant
article Full Article subject Summary summarize Notecard
  1. Results from a phase I clinical trial demonstrated sustained treatment responses to chimeric antigen receptor T-cell therapy in pediatric patients with neuroblastoma.
  2. A complete remission lasting more than 18 years was observed in one patients, highlighting the potential of GD2 CAR-ATC/VST therapy in achieving long-term disease control.
  3. Sensorineural hearing loss was the most common treatment-related adverse event.
  4. This study represents, potentially, the longest reported survival after CAR T-cell therapy for active malignancy, emphasizing its potential for improving outcomes in children with refractory/relapsed neuroblastoma.

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.